India to Venezuela: Acetaminophen Export Trade Route

To import Acetaminophen formulations into Venezuela, the following approvals and registrations are mandatory:

• Sanitary Registration: All pharmaceutical products must obtain a Sanitary Registration from the NDRA. This involves submitting a comprehensive product registration dossier, which includes detailed information on the product's composition, therapeutic purpose, manufacturing process, quality control measures, clinical evidence, labeling, and safety profile.

• Dossier Format: The registration dossier should be compiled in the Common Technical Document (CTD) format, aligning with international standards for pharmaceutical documentation.

• Good Manufacturing Practice (GMP) Certificates: As of July 1, 2023, it is mandatory to submit GMP certificates for both the finished product and the active pharmaceutical ingredient (API) manufacturers. These certificates must be issued by the relevant health authorities in the country of origin, signed, sealed, and legalized (apostilled).

• Import License: An import license or authorization from the National Institute of Drug and Food Control (INCANAM), under the Ministry of Popular Power for Health (MPPS), is required for all pharmaceutical imports.

• Documentation: Essential documents include the Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (CoA), Free Sale Certificate, Bill of Lading, Packing List, and Material Safety Data Sheet (MSDS).

• Timelines and Fees: The approval timelines and product registration fees can vary. Dossier reviews may be time-consuming, and stability data should correspond to Venezuela's local climate zone.

Indian exporters of Acetaminophen formulations must comply with the following GMP standards to supply products to Venezuela:

• GMP Certification: Manufacturing facilities must hold valid GMP certificates issued by recognized health authorities. These certifications ensure that manufacturing processes adhere to globally recognized standards for pharmaceutical production.

• Facility Approval: While specific details on currently approved Indian facilities are not publicly disclosed, exporters should ensure their manufacturing sites meet Venezuela's regulatory requirements.

• Regulatory Actions: As of March 2026, there have been no publicly reported regulatory actions by the NDRA against Indian pharmaceutical companies supplying to Venezuela.

Several regulatory developments have impacted Indian pharmaceutical exports to Venezuela in the past 18 months:

• GMP Certificate Requirement: Effective July 1, 2023, Venezuela mandated the submission of GMP certificates for both finished product and API manufacturers as part of the Sanitary Registration process.

• API and Raw Material Supply: In February 2025, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) received a request from the Indian Embassy in Venezuela to facilitate the supply of APIs and raw materials for pharmaceutical manufacturing in Venezuela. Pharmexcil urged member companies with Stringent Regulatory Authority (SRA) approvals to respond promptly.

• Essential Medicines Demand: In July 2025, the Venezuelan Ministry of Education expressed a formal requirement for essential medicines, presenting an export opportunity for Indian pharmaceutical companies. Pharmexcil coordinated this initiative, inviting SRA-approved exporters to express interest.

These developments underscore the importance of compliance with Venezuela's evolving regulatory landscape for successful pharmaceutical exports.

As of 2025, the global acetaminophen market was valued at USD 11.01 billion, with projections indicating growth to USD 16.44 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 4.56%. While specific data for Venezuela is limited, the country's demand for acetaminophen formulations is influenced by several factors:

• Disease Prevalence: High incidences of common ailments such as headaches, fevers, and body aches drive the consistent use of acetaminophen for pain and fever relief.

• Healthcare Spending: Economic challenges have impacted healthcare infrastructure and spending, yet acetaminophen remains a cost-effective option for symptom management.

• Aging Population: An aging demographic contributes to increased demand for analgesics to manage age-related conditions.

• Universal Health Coverage: Efforts to improve healthcare access may influence the availability and consumption of over-the-counter medications like acetaminophen.

Venezuela's pharmaceutical sector faces challenges, including economic instability and supply chain disruptions, affecting both domestic manufacturing and importation of medicines. The country relies on imports to meet its pharmaceutical needs, with India being a notable supplier of finished acetaminophen formulations.

Venezuela maintains a 0% import duty on finished pharmaceutical products classified under HS code 30049069, including acetaminophen formulations. This duty-free status applies universally, as there are no specific Free Trade Agreements (FTAs) between Venezuela and India affecting pharmaceutical tariffs. Additionally, there are no reported anti-dumping duties on these imports.

India is a significant supplier of finished acetaminophen formulations to Venezuela, accounting for approximately 0.5% of India's total exports of these products, valued at $1.1 million USD across 113 shipments from 34 Indian manufacturers. The top Indian exporters include Deutsche Labs Inc., Gracious Pharmaceuticals Private Limited, Lucent Biotech Limited, S.D. Pharmaceuticals, and Kwality Pharmaceuticals Limited.

Other major countries supplying acetaminophen formulations to Venezuela include China and various European Union manufacturers. India's competitive pricing, coupled with the duty-free import status in Venezuela, enhances its position in the market. However, specific data on India's share of Venezuela's total acetaminophen imports and comparative pricing with competitors is not readily available.

1. Verify Manufacturer's Registration with CDSCO: Confirm that the Indian supplier is registered with the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940. This registration ensures the manufacturer operates legally within India's pharmaceutical regulatory framework.

2. Assess GMP Certification Validity: Ensure the manufacturer holds a valid Good Manufacturing Practice (GMP) certificate, compliant with Schedule M of the Drugs and Cosmetics Rules, 1945. This certification indicates adherence to quality manufacturing standards.

3. Review Drug Master File (DMF): Obtain and evaluate the supplier's DMF, which provides detailed information on the manufacturing process, controls, and specifications of the Acetaminophen formulations.

4. Confirm WHO-GMP Certification: For international credibility, verify if the manufacturer possesses WHO-GMP certification, aligning with global quality standards.

5. Evaluate Quality Management Systems: Assess the supplier's quality management systems, including Standard Operating Procedures (SOPs), quality control measures, and compliance with Good Laboratory Practices (GLP).

6. Check Export History and Compliance: Review the supplier's export history to ensure consistent compliance with international regulatory standards and successful market entries.

7. Request Stability Data: Obtain stability data for the Acetaminophen formulations, ensuring they meet the climatic conditions of Venezuela (ICH Zone IV).

8. Conduct Financial Due Diligence: Assess the financial stability of the supplier to ensure they can fulfill long-term contractual obligations.

9. Plan for On-Site Audits: Schedule an on-site audit of the manufacturing facility to verify compliance with GMP standards and assess production capabilities.

10. Establish Legal Agreements: Draft comprehensive contracts outlining quality expectations, delivery schedules, and compliance requirements to safeguard both parties' interests.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified quality standards.

2. Certificate of Origin (CoO): Certifies that the Acetaminophen formulations are manufactured in India, which may impact tariff and import regulations.

3. GMP Certificate: Issued by CDSCO, this document verifies that the manufacturing facility complies with GMP standards.

4. Stability Data: Demonstrates the product's shelf-life and stability under various environmental conditions, ensuring efficacy throughout its intended use.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive information on the manufacturing process, controls, and specifications of the product.

7. Free Sale Certificate: Issued by CDSCO, indicating that the product is approved for sale in India and is freely sold in the domestic market.

8. Insurance Certificates: Proof of liability insurance covering potential risks associated with the product, providing financial protection.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies such as the US FDA or WHO-GMP suspensions indicate serious compliance issues.

2. Unrealistically Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf-life and efficacy.

4. Limited Export Experience: Suppliers without a proven track record in international markets may lack the necessary expertise to meet global regulatory standards.

5. Resistance to Audits: Hesitation or refusal to allow on-site inspections suggests potential compliance or quality issues.

6. Inadequate Documentation: Incomplete or inconsistent documentation, such as missing CoAs or batch records, indicates poor quality management systems.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including GMP certificates, SOPs, and previous audit reports, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Document any non-conformities identified during the audit and require the supplier to implement corrective actions within a specified timeframe.

4. Annual Re-Qualification Process: Schedule regular audits, at least annually, to ensure ongoing compliance and continuous improvement.

5. Remote Monitoring Options: Utilize technology for virtual audits, document reviews, and regular communication to maintain oversight between on-site inspections.

6. Cost Estimates and Timeline: Budget approximately $5,000 to $10,000 USD for an on-site audit, including travel expenses, with the process typically taking 3 to 5 days.

By adhering to this comprehensive approach, Venezuelan companies can establish reliable partnerships with Indian suppliers, ensuring the consistent quality and safety of Acetaminophen formulations imported into their market.